Clinical Trials | October 27, 2022
Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial
Results reinforce commitment to next-generation oral SERD development programme
Results reinforce commitment to next-generation oral SERD development programme
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
Study achieves primary endpoint of radiographic progression-free survival
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
Subscribe To Our Newsletter & Stay Updated
